FDA Approves Labeling for RLD, NDA N021411

The Food and Drug Administration (FDA) has approved the labeling for Reference Listed Drug (RLD) and New Drug Application (NDA) N021411, as indicated by the filing date of March 13, 2026. This action pertains to the specific requirements for drug labeling as part of the FDA's regulatory oversight.

This notice is primarily informational for drug manufacturers and other stakeholders in the pharmaceutical industry. While no immediate compliance actions are mandated by this specific notice, it signifies an approved labeling status for the mentioned NDA. Companies involved with this application should ensure their internal documentation and external product labeling align with the FDA's approved specifications.